Last updated: 2026-09-05 13:12:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
LENZ Therapeutics, Inc. (LENZ) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $5.97, with a market capitalization of $182.24M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.54 to $50.40. This page covers its latest market performance, valuation, price trends and company information.
$182.24M | |
$5.75 | |
$50.40 | |
$4.54 | |
$5.83 | |
442.72K | |
-- | |
-- | |
$50.40 | |
$4.54 | |
-- | |
-- |
LENZ Therapeutics, Inc. (LENZ) last closed at $5.83 as of 2026-09-04 23:42:00, unchanged from the previous close of $5.83.
During the latest regular trading session, LENZ traded between $4.54 and $50.40, with a volume of 442.72K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, LENZ Therapeutics, Inc. (LENZ) moved from $5.06 to $5.97, representing a gain of 17.89% ($0.91).
The stock traded between $5.62 and $5.97 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 679.45 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.1%
LENZ is currently trading at $5.97, placing it 3.1% of the way from its 52-week low of $4.54 to its 52-week high of $50.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 152 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of LENZ Therapeutics, Inc. (LENZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.